Bristol-Myers Squibb

Boosted REYATAZ proves effective in men and women

Friday, July 22, 2011 10:16 AM

Bristol-Myers Squibb released results from a long-term European cohort study that included 1,294 antiretroviral (ARV)-experienced patients from Germany, France and Sweden.

More... »

Pharmasset, Tibotec collaborate in hepatitis C study

Friday, July 8, 2011 12:32 PM

Pharmasset has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate in a phase II study the safety and efficacy of PSI-7977 in combination with TMC435, for the treatment of chronic hepatitis C virus (HCV).

More... »

Merck Serono changes R&D organizational structure

Thursday, July 7, 2011 02:02 PM

Merck Serono, a division of Merck of Darmstadt, Germany, is putting a new organizational structure for research and development into effect. Two dedicated groups, focusing on different stages of pharmaceutical innovation (pre- and post- proof-of-concept), will be created as a first step in redesigning Merck Serono's R&D model.

More... »

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »

Innovative paperless clinical trial study highlights time and cost savings

Friday, April 15, 2011 11:11 AM

Using interoperable digital identities, digital signatures and cloud computing can accelerate the initiation of a clinical trial and also lower costs, report a group of government and industry cancer researchers. They participated in the phase I of a pilot study that used interoperable digital identities and cloud-based digital signatures to eliminate reliance on paper forms in clinical trials.

More... »

Lexicon Pharmaceuticals names Dr. Pablo Lapuerta CMO

Tuesday, March 29, 2011 12:15 PM

Lexicon Pharmaceuticals has named Pablo Lapuerta, M.D., chief medical officer. He will be responsible for directing clinical development of Lexicon's drug candidates from phase II proof-of-concept through phase III and approval.

More... »

EMA seeks public comment on biomarker

Wednesday, March 2, 2011 01:49 PM

The European Medicines Agency (EMA) is seeking public comment on the first clinical biomarker the agency has approved for use in humans, according to a report in PharmaTimes.

More... »

More big pharmaceuticals join trend of partnering with CROs to cut costs, speed drug development

Monday, October 11, 2010 10:27 AM

Major pharmaceutical companies are increasingly forming long-term, strategic partnerships with a small number of global contract research organizations (CROs) in order to cut costs and streamline their outsourced clinical work.

More... »

CT Approvals Down, Global Participation Up in Russia Q2

Wednesday, September 2, 2009 07:19 AM

According to an Orange Paper released by Russia-based CRO, Synergy Research Group, Russia’s health agency, the Federal Service on Surveillance in Healthcare and Social Development (RosZdraNadzor, RZN) approved only 129 new clinical trials, including local and bioequivalence studies, during Q2 2009, representing a 17% decrease from Q2 last year. The percentage of approved multinational clinical trials increased slightly, however, to 65% of the total during this time period.

More... »